Audentes Therapeutics, Inc. (NASDAQ:BOLD) VP Suyash Prasad sold 8,000 shares of the firm’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $21.44, for a total transaction of $171,520.00. Following the completion of the sale, the vice president now owns 8,000 shares in the company, valued at approximately $171,520. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Shares of Audentes Therapeutics, Inc. (NASDAQ BOLD) opened at 21.98 on Monday. The firm has a 50-day moving average of $19.99 and a 200-day moving average of $17.20. The firm’s market cap is $610.69 million. Audentes Therapeutics, Inc. has a 12 month low of $13.13 and a 12 month high of $22.82.

Audentes Therapeutics (NASDAQ:BOLD) last issued its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.87) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.77) by $0.10. On average, analysts anticipate that Audentes Therapeutics, Inc. will post ($3.53) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Audentes Therapeutics, Inc. (BOLD) VP Sells $171,520.00 in Stock” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/09/04/audentes-therapeutics-inc-bold-vp-sells-171520-00-in-stock.html.

Institutional investors have recently made changes to their positions in the company. Wells Fargo & Company MN boosted its stake in shares of Audentes Therapeutics by 278.5% in the 1st quarter. Wells Fargo & Company MN now owns 7,747 shares of the biotechnology company’s stock valued at $132,000 after purchasing an additional 5,700 shares in the last quarter. Nationwide Fund Advisors boosted its stake in shares of Audentes Therapeutics by 288.9% in the 2nd quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock valued at $164,000 after purchasing an additional 6,384 shares in the last quarter. Citadel Advisors LLC purchased a new stake in shares of Audentes Therapeutics in the 1st quarter valued at $184,000. State of Wisconsin Investment Board purchased a new stake in shares of Audentes Therapeutics in the 2nd quarter valued at $210,000. Finally, Rhumbline Advisers purchased a new stake in shares of Audentes Therapeutics in the 2nd quarter valued at $252,000. 77.01% of the stock is owned by institutional investors.

A number of analysts have weighed in on BOLD shares. Zacks Investment Research upgraded shares of Audentes Therapeutics from a “sell” rating to a “hold” rating and set a $17.00 target price on the stock in a research report on Wednesday, May 10th. Wedbush restated an “ourperform” rating and issued a $20.00 target price on shares of Audentes Therapeutics in a research report on Monday, May 15th. ValuEngine upgraded shares of Audentes Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, July 20th. Finally, Evercore ISI started coverage on shares of Audentes Therapeutics in a research report on Wednesday, August 16th. They issued an “outperform” rating and a $23.00 target price on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $22.40.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Receive News & Stock Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related stocks with our FREE daily email newsletter.